{"id":4416,"date":"2019-03-26T05:08:03","date_gmt":"2019-03-26T05:08:03","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/?post_type=study_trials&#038;p=4416"},"modified":"2019-11-12T15:29:51","modified_gmt":"2019-11-12T15:29:51","slug":"everolimus-y-anakinra-o-denosumab-en-el-tratamiento-de-participantes-con-canceres-avanzados-recidivantes-o-refractarios","status":"publish","type":"study_trials","link":"https:\/\/www.erdheim-chester.org\/es\/study_trials\/everolimus-and-anakinra-or-denosumab-in-treating-participants-with-relapsed-or-refractory-advanced-cancers\/","title":{"rendered":"Everolimus y anakinra o denosumab en el tratamiento de pacientes con c\u00e1nceres avanzados recidivantes o refractarios"},"content":{"rendered":"<p><strong>Objetivo del estudio:&nbsp;<\/strong>&nbsp;El objetivo de este estudio cl\u00ednico de fase I es determinar la dosis tolerable de la combinaci\u00f3n de Afinitor (everolimus) con Kineret (anakinra) o con Xgeva (denosumab) en pacientes con c\u00e1ncer avanzado. El everolimus est\u00e1 dise\u00f1ado para impedir que las c\u00e9lulas se dividan.\u00a0 La anakinra est\u00e1 indicada para bloquear una prote\u00edna que interviene en el desarrollo del tumor, la formaci\u00f3n de nuevos vasos sangu\u00edneos y la diseminaci\u00f3n del c\u00e1ncer.  El denosumab est\u00e1 dise\u00f1ado para bloquear la actividad de una prote\u00edna, lo que podr\u00eda prevenir complicaciones \u00f3seas en los casos de c\u00e1ncer que se ha diseminado a los huesos.<br \/>\n<strong>Patrocinador:&nbsp;&nbsp;<\/strong>Centro Oncol\u00f3gico M.D. Anderson<br \/>\n<strong>Datos de contacto del ensayo:&nbsp;&nbsp;<\/strong>Ver\u00f3nica Holley; VRHolley@mdanderson.org Filip Janku; 713-563-1930; FJanku@mdanderson.org<br \/>\n<strong>Participaci\u00f3n solicitada del paciente:&nbsp;&nbsp;<\/strong>Pacientes con ECD de al menos 18 a\u00f1os de edad. Los pacientes pueden ser BRAF positivos o negativos.<br \/>\n<strong>Centros conocidos que admiten a pacientes con ECD en el ensayo:&nbsp;<\/strong>&nbsp;MD Anderson, Houston, Texas<br \/>\n<strong>Identificador de ClinicalTrials.gov:<\/strong>&nbsp; NCT01624766<\/p>","protected":false},"excerpt":{"rendered":"<p>Study Objective:&nbsp;&nbsp;The goal of this Phase I clinical research study is to determine the tolerable dose of the combination of Afinitor (everolimus) either with Kineret (anakinra) or Xgeva (denosumab) for [&hellip;]<\/p>\n","protected":false},"featured_media":0,"parent":0,"menu_order":0,"template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"","wds_primary_study_trials_cat":0,"_links_to":"","_links_to_target":""},"study_trials_cat":[32],"class_list":["post-4416","study_trials","type-study_trials","status-publish","hentry","study_trials_cat-drug-trial"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/es\/wp-json\/wp\/v2\/study_trials\/4416","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/es\/wp-json\/wp\/v2\/study_trials"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/es\/wp-json\/wp\/v2\/types\/study_trials"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/es\/wp-json\/wp\/v2\/media?parent=4416"}],"wp:term":[{"taxonomy":"study_trials_cat","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/es\/wp-json\/wp\/v2\/study_trials_cat?post=4416"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}